Genetically Engineered Mesenchymal Stromal Cells As a New Trend for Treatment of Severe Acute Graft-Versus-Host Disease Publisher Pubmed



Shahbaz SK¹ ; Mansourabadi AH^{2, 3} ; Jafari D^{4, 5} Show Affiliations
Source: Clinical and Experimental Immunology Published:2022

Abstract

Mesenchymal stem cells (MSCs) are a population of non-hematopoietic and self-renewing cells characterized by the potential to differentiate into different cell subtypes. MSCs have interesting features which have attracted a lot of attention in various clinical investigations. Some basic features of MSCs are including the weak immunogenicity (absence of MHC-II and costimulatory ligands accompanied by the low expression of MHC-I) and the potential of plasticity and multi-organ homing via expressing related surface molecules. MSCs by immunomodulatory effects could also ameliorate several immune-pathological conditions like graft-versus-host diseases (GVHD). The efficacy and potency of MSCs are the main objections of MSCs therapeutic applications. It suggested that improving the MSC immunosuppressive characteristic via genetic engineering to produce therapeutic molecules consider as one of the best options for this purpose. In this review, we explain the functions, immunologic properties, and clinical applications of MSCs to discuss the beneficial application of genetically modified MSCs in GVHD. © 2022 The Author(s). All rights reserved.